“…3 Eisai Ltd. European Knowledge Centre,Hatfield,UK,4 Eisai Inc.,Woodcliff Lake,NJ,5 GA Thompson Consulting,6 Science Faculty,Dept. of Pharmaceutical Sciences,Utrecht University,Utrecht,The Netherlands Background Lenvatinib (E7080) is an orally available multitargeted tyrosine kinase inhibitor with anti-angiogenic and antitumour activity (Matsui et al 2008;Glen et al 2011).To gain more insight into the disposition of lenvatinib, a mass balance study was performed in patients with advanced solid tumours.…”